Maravai Lifesciences Valuation
| MRVI Stock | USD 2.27 0.13 5.42% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Maravai Lifesciences secures a last-minute Real Value of $2.18 per share. The latest price of the firm is $2.27. Our model forecasts the value of Maravai Lifesciences from analyzing the firm fundamentals such as Profit Margin of (0.56) %, return on equity of -0.38, and Current Valuation of 379.66 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Maravai Lifesciences' valuation include:
Price Book 1.0002 | Enterprise Value | Enterprise Value Ebitda 1.7702 | Price Sales 2.2226 | Forward PE 370.3704 |
Overvalued
Today
Please note that Maravai Lifesciences' price fluctuation is dangerous at this time. Calculation of the real value of Maravai Lifesciences is based on 3 months time horizon. Increasing Maravai Lifesciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Maravai Lifesciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Maravai Stock. However, Maravai Lifesciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.27 | Real 2.18 | Target 9.07 | Hype 2.27 | Naive 2.52 |
The intrinsic value of Maravai Lifesciences' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Maravai Lifesciences' stock price.
Estimating the potential upside or downside of Maravai Lifesciences Holdings helps investors to forecast how Maravai stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Maravai Lifesciences more accurately as focusing exclusively on Maravai Lifesciences' fundamentals will not take into account other important factors: When choosing an evaluation method for Maravai Lifesciences, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Maravai Lifesciences Cash |
|
Maravai Valuation Trend
Maravai Lifesciences' real value analysis enables investors to forecast the earnings more efficiently. Using both Maravai Lifesciences' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Maravai Revenue by Product
Maravai Lifesciences Total Value Analysis
Maravai Lifesciences Holdings is now anticipated to have valuation of 379.66 M with market capitalization of 576.07 M, debt of 37.34 M, and cash on hands of 617.45 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Maravai Lifesciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
379.66 M | 576.07 M | 37.34 M | 617.45 M |
Maravai Lifesciences Investor Information
About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.0. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Maravai Lifesciences recorded a loss per share of 1.05. The entity had not issued any dividends in recent years. Based on the key indicators related to Maravai Lifesciences' liquidity, profitability, solvency, and operating efficiency, Maravai Lifesciences Holdings is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Maravai Lifesciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Maravai Lifesciences has an asset utilization ratio of 25.71 percent. This signifies that the Company is making $0.26 for each dollar of assets. An increasing asset utilization means that Maravai Lifesciences Holdings is more efficient with each dollar of assets it utilizes for everyday operations.Maravai Lifesciences Ownership Allocation
Maravai Lifesciences maintains a total of 143.65 Million outstanding shares. The majority of Maravai Lifesciences outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Maravai Lifesciences Holdings to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Maravai Lifesciences. Please pay attention to any change in the institutional holdings of Maravai Lifesciences as this could imply that something significant has changed or is about to change at the company. Also note that almost one hundred seventy-two thousand three hundred eighty-two invesors are currently shorting Maravai Lifesciences expressing very little confidence in its future performance.Maravai Lifesciences Profitability Analysis
The company reported the previous year's revenue of 259.19 M. Net Loss for the year was (259.62 M) with profit before overhead, payroll, taxes, and interest of 108.31 M.About Maravai Lifesciences Valuation
An absolute valuation paradigm, as applied to Maravai Stock, attempts to find the value of Maravai Lifesciences based on its fundamental and basic technical indicators. By analyzing Maravai Lifesciences's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Maravai Lifesciences's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Maravai Lifesciences. We calculate exposure to Maravai Lifesciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Maravai Lifesciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 108.3 M | 102.9 M | |
| Pretax Profit Margin | (1.01) | (0.96) | |
| Operating Profit Margin | (0.91) | (0.86) | |
| Net Loss | (0.56) | (0.53) | |
| Gross Profit Margin | 0.42 | 0.67 |
Maravai Lifesciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 137.9 M | |
| Quarterly Earnings Growth Y O Y | -0.327 | |
| Forward Price Earnings | 370.3704 |
Maravai Lifesciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Maravai Lifesciences Holdings and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Maravai we look at many different elements of the entity such as Maravai's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Maravai Lifesciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Maravai Lifesciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Maravai Lifesciences' worth.Complementary Tools for Maravai Stock analysis
When running Maravai Lifesciences' price analysis, check to measure Maravai Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maravai Lifesciences is operating at the current time. Most of Maravai Lifesciences' value examination focuses on studying past and present price action to predict the probability of Maravai Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maravai Lifesciences' price. Additionally, you may evaluate how the addition of Maravai Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stocks Directory Find actively traded stocks across global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |